The Fort Worth Press - Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

USD -
AED 3.672498
AFN 64.999682
ALL 81.827235
AMD 365.160186
ANG 1.789785
AOA 917.999742
ARS 1544.481598
AUD 1.46107
AWG 1.8
AZN 1.706428
BAM 1.762379
BBD 2.036128
BDT 126.028385
BGN 1.747831
BHD 0.381383
BIF 3024.210446
BMD 1
BND 1.292395
BOB 11.989636
BRL 5.583699
BSD 1.010945
BTN 95.007435
BWP 13.869176
BYN 3.0269
BYR 19600
BZD 2.033164
CAD 1.426105
CDF 2314.999732
CHF 0.833275
CLF 0.024992
CLP 983.609895
CNY 6.67035
CNH 6.66699
COP 3280.9
CRC 457.263359
CUC 1
CUP 24.260419
CVE 99.36917
CZK 22.02055
DJF 180.019916
DKK 6.750195
DOP 61.316908
DZD 136.897983
EGP 53.547704
ERN 15
ETB 164.541452
EUR 0.902992
FJD 2.26815
FKP 0.753031
GBP 0.754375
GEL 2.598309
GGP 0.753031
GHS 11.838234
GIP 0.753031
GMD 73.999988
GNF 8956.017465
GTQ 7.724958
GYD 211.837332
HKD 7.84405
HNL 27.174457
HRK 6.76901
HTG 132.510848
HUF 329.413982
IDR 18235.95
ILS 3.174849
IMP 0.753031
INR 93.831985
IQD 1532.417211
IRR 1906074.999698
ISK 123.350474
JEP 0.753031
JMD 160.446988
JOD 0.708962
JPY 159.782495
KES 129.960042
KGS 87.449603
KHR 4122.94022
KMF 442.000317
KPW 899.999961
KRW 1332.774996
KWD 0.31137
KYD 0.842352
KZT 451.299842
LAK 22755.230323
LBP 90528.995629
LKR 335.972315
LRD 171.855991
LSL 16.573648
LTL 2.95274
LVL 0.60489
LYD 6.480393
MAD 9.86162
MDL 18.166334
MGA 4574.394744
MKD 55.575371
MMK 2099.724407
MNT 3604.903758
MOP 8.167515
MRU 40.781511
MUR 47.169835
MVR 15.399797
MWK 1752.977277
MXN 18.605976
MYR 4.081897
MZN 63.89969
NAD 16.571931
NGN 1345.740046
NIO 37.201087
NOK 9.569402
NPR 152.012581
NZD 1.797825
OMR 0.384506
PAB 1.010972
PEN 3.44501
PGK 4.540191
PHP 63.663007
PKR 277.574021
PLN 3.983398
PYG 6240.678409
QAR 3.685126
RON 4.827105
RSD 106.191869
RUB 83.07543
RWF 1495.696841
SAR 3.772213
SBD 8.090747
SCR 13.937946
SDG 601.50203
SEK 9.985755
SGD 1.285215
SHP 0.749316
SLE 22.902058
SLL 20969.504398
SOS 577.749741
SRD 37.645974
STD 20697.981008
STN 22.079133
SVC 8.845235
SYP 13001.999685
SZL 16.578126
THB 33.783503
TJS 9.290497
TMT 3.5
TND 3.012932
TOP 2.40776
TRY 50.261103
TTD 6.855598
TWD 32.930497
TZS 2658.158982
UAH 45.980237
UGX 4124.816943
UYU 40.90479
UZS 12104.528047
VES 900.490495
VND 25682
VUV 119.943861
WST 2.787799
XAF 592.324219
XAG 0.019376
XAU 0.000251092251
XCD 2.70255
XCG 1.821762
XDR 0.707052
XOF 592.324219
XPF 107.465645
YER 236.503327
ZAR 16.6022
ZMK 9001.199211
ZMW 20.597486
ZWL 321.999592
SSP 5786.523514
MXV 2.090565
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy
Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

TAMPA, FLORIDA / ACCESS Newswire / August 14, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the termination of its equity purchase agreement ("ELOC") with Hudson Global Ventures, LLC.

Text size:

The ELOC was an effective tool that nearly doubled the Company's original IPO raise. The decision to terminate the agreement reflects a strategic shift toward accretive financing and reinforces its aim of long-term shareholder value creation.

Management cited strong execution in expanding its independent pharmacy network, accelerating adoption of its AI-powered prescription routing technology and payment platforms, and creating a strong pipeline for growth opportunities with manufacturer direct-to-patient (DTP) platforms as drivers behind the move. This unique approach is designed to bypass traditional PBM barriers, increase manufacturer margins, and accelerate patient access.

"From a financial standpoint, terminating the ELOC aligns with our disciplined approach to capital structure and shareholder equity preservation," said Mark DiSiena, Chief Financial Officer of Wellgistics Health. "It allows us to secure more favorable funding opportunities so we can focus on our strategic plans, optimize our cost of capital, and pursue options that better reflect our growth trajectory."

"This decision reflects the discipline we're bringing to every part of the business," said Brian Norton, Chief Executive Officer of Wellgistics Health. "We've moved past the challenges of our opening quarters and are entering a new chapter built on operational strength and strategic execution. We're ready to show the market what we're truly capable of - delivering smarter, faster access to medicine, empowering independent pharmacies, and creating lasting value across the healthcare ecosystem."

About Wellgistics Health

Wellgistics Health (NASDAQ:WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ independent pharmacies and 200+ U.S. manufacturers, providing wholesale distribution, digital prescription routing, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health offers compliant, end-to-end solutions that restore access, transparency, and trust in U.S. healthcare.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, market conditions and other risks detailed in our reports and statements filed with the SEC. Investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Media Contact: [email protected]

Investor Relations: [email protected]

Investor Relations Contact:

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

G.Dominguez--TFWP